<p>美国银行证券分析师 Alec Stranahan 昨日重申了对 Agios Pharma 的买入评级，并设定了 41.00 美元的目标价。该公司股票昨日收于 28.42 美元。</p>
<h3>在 TipRanks 上享受 55% 的折扣</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>发现表现优异的股票创意，并升级到市场领先者的投资组合，使用智能投资者精选</li>
</ul>
<p>Stranahan 覆盖医疗保健行业，关注 Moderna、Beam Therapeutics 和 Revolution Medicines 等股票。根据 TipRanks 的数据，Stranahan 的平均回报率为 10.3%，推荐股票的成功率为 52.78%。</p>
<p>除了美国银行证券，Agios Pharma 还在 4 月 30 日获得了 Truist Financial 的 Gregory Renza 的买入评级。然而，在 4 月 29 日，RBC Capital 对 Agios Pharma（纳斯达克：AGIO）维持了持有评级。</p>

Agios制药

<p>美国银行证券分析师 Alec Stranahan 重申了对 Agios Pharma（AGIO）的买入评级，目标价为 41.00 美元，而该股收盘价为 28.42 美元。专注于医疗保健行业的 Stranahan 平均回报率为 10.3%，成功率为 52.78%。此外，Agios Pharma 还获得了 Truist Financial 的买入评级，而 RBC Capital 则维持了持有评级</p>

<p>Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on Agios Pharma yesterday and set a price target of $41.00. The company’s shares closed yesterday at $28.42.</p>
<div class="lb-trans"><p>美国银行证券分析师 Alec Stranahan 昨日重申了对 Agios Pharma 的买入评级，并设定了 41.00 美元的目标价。该公司股票昨日收于 28.42 美元。</p>
</div><h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>在 TipRanks 上享受 55% 的折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>发现表现优异的股票创意，并升级到市场领先者的投资组合，使用智能投资者精选</li>
</ul>
</div><p>Stranahan covers the Healthcare sector, focusing on stocks such as Moderna, Beam Therapeutics, and Revolution Medicines. According to TipRanks, Stranahan has an average return of 10.3% and a 52.78% success rate on recommended stocks.</p>
<div class="lb-trans"><p>Stranahan 覆盖医疗保健行业，关注 Moderna、Beam Therapeutics 和 Revolution Medicines 等股票。根据 TipRanks 的数据，Stranahan 的平均回报率为 10.3%，推荐股票的成功率为 52.78%。</p>
</div><p>In addition to Bank of America Securities, Agios Pharma also received a Buy from Truist Financial’s Gregory Renza in a report issued on April 30. However, on April 29, RBC Capital maintained a Hold rating on Agios Pharma (NASDAQ: AGIO).</p>
<div class="lb-trans"><p>除了美国银行证券，Agios Pharma 还在 4 月 30 日获得了 Truist Financial 的 Gregory Renza 的买入评级。然而，在 4 月 29 日，RBC Capital 对 Agios Pharma（纳斯达克：AGIO）维持了持有评级。</p>
</div>

Bank of America Securities Sticks to Their Buy Rating for Agios Pharma (AGIO)

Tip Ranks

美国银行

Moderna

Beam Therapeutics

Revolution Medicines

Truist Financial

加拿大皇家银行

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM)

美国银行证券维持对 Agios 制药（AGIO）的买入评级